Navigation Links
Access Pharmaceuticals to Present Data on ProLindac(TM) at the AACR-NCI-EORTC 'Molecular Targets and Cancer Therapeutics' Conference
Date:10/18/2007

DALLAS, Oct. 18 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) announced today that its collaborators will be presenting clinical and preclinical data on its lead anticancer compound, ProLindac(TM), at the joint symposium of the American Association for Cancer Research (AACR), National Cancer Institute (NCI) and European Organization for Research and Treatment of Cancer (EORTC) entitled "International Conference Molecular Targets and Cancer Therapeutics: Discovery, Biology, and Clinical Applications" taking place October 22-26, 2007 at the Moscone Convention Center West in San Francisco, CA.

An update on Access' ongoing ProLindac Phase 2 clinical study will be presented during Poster Session A, "Clinical Trials" in Abstract #A145 entitled "AP5346, a pH-dependent polymer-vectorized DACH, is safe at pharmacodynamically active doses: Results from an ongoing phase II trial in borderline potentially platinum-sensitive ovarian cancer (OC) patients" on Tuesday, October 23, 2007 from 12:30 p.m. PDT.

New ProLindac preclinical data will appear in two posters presented during Poster Session C, Novel Drug Delivery Systems, on Thursday, October 25, 2007 from 12:30 p.m. PDT:

Abstract #C105 : "Molecular and cellular effects of AP5346, a novel DACH- platinum linked polymer-compound, compared to oxaliplatin and cisplatin in a panel of human cancer cell lines."

Abstract #C110: "Antiproliferative activity of AP5346, a novel DACH- platinum compound, alone and in combination with other cytotoxics, in human colon and ovarian cancer cells."

ProLindac is a novel DACH platinum prodrug which has been shown to be active in a wide variety of solid tumors in both preclinical models and in human trials. Access believes that ProLindac's unique molecular design potentially could eliminate some of the toxic side effects seen in the currently marketed DACH platinum, Eloxatin, which has sales in excess of $2 billion.

About
'/>"/>

SOURCE Access Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. PromegaExpress Expands Easy Access to Products with New Cabinet
2. Access and Somanta Announce Data to be Presented on Angiolix at ASCO Oncology Conference
3. Access Pharmaceuticals Announces Poster Presentations on ProLindac at the American Association for Cancer Research 2007 Annual Meeting
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
10. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...LIN LAKES, N.J., Nov. 20 ... today announced the completion of its acquisition...ompany that develops and manufactures molecular di... May 2009, BD and HandyLab announced an exclusive ...cular assays on the HandyLab Jaguar(TM) platform, ...
(Date:11/19/2009)... France, Nov. 19 In response to an...erous and illegal medicines, Operation Pangea II, ...L and the World Health Organization,s Internationa...IMPACT) to highlight the dangers of buying medicin...esulted in a series of arrests and the seizure of ...
(Date:11/19/2009)...TT PARK, Ill., Nov. 19 ...BT ) as one of its Most Admired Corporate Dealmake...nored Abbott as its Most Admired Dealmaker in phar... acquisitions and divestitures since January 2006....ts business portfolio with a focus on high-growth,...
Breaking Medicine Technology:BD Completes Acquisition of HandyLab, Inc. 2BD Completes Acquisition of HandyLab, Inc. 3International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 1PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 2PEAK Surgical Announces Results of First PRECISE Studies at American College of Surgeons Clinical Congress 5492 3At Waters Forum Rep DeLauro Administration Urge Congress to Improve the Safety of Imported Food 59483 1At Waters Forum Rep DeLauro Administration Urge Congress to Improve the Safety of Imported Food 59483 2At Waters Forum Rep DeLauro Administration Urge Congress to Improve the Safety of Imported Food 59483 3Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 59481 1Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 59481 2Quicker Referral for Gallbladder Operation Could Save 50 Percent of Preoperative Treatment Charges 59481 3
...E, Conn., Dec. 7 /PRNewswire-FirstCall/-- Soliris(...veloped by Alexion Pharmaceuticals, Inc.,(Nasdaq: ... hemoglobinuria (PNH),was associated with an impro...er of patients with two other rare and severe comp...ical trial, according to patient cases presented,t...
..., Dec. 6 Phase III data on carisbamate, an,invest... the adjunctive,treatment of partial onset seizure... presented today during the poster sessions of the...ety. , Results from two identical placebo-co...y, safety and tolerability of carisbamate as an,ad...
Other Medicine Technology:First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting 2First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting 3First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting 4First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting 5First Clinical Experience With Soliris(R) in Treating Patients With Two Rare Complement-Mediated Diseases Presented at ASH Annual Meeting 6Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 2Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 3Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 4Phase III Data Demonstrate Efficacy and Tolerability of Carisbamate as an Adjunctive Therapy for Partial Onset Seizures 5
(Date:11/21/2009)...PRNewswire-USNewswire/ -- A regional initiative la...iver blindness) in the Americas has substantially ...ars, as evidenced by a 31% decrease in the number ...in six endemic countries. Results were reported t...ciety of Tropical Medicine and Hygiene (ASTMH). ,...
(Date:11/21/2009)...ve medical apparel company launches men,s lab coat... San Clemente, Calif. (PRWEB) November 21, 200...apparel, today announced the launch of its men,s l...eading international trade fair for the medical in...urates its men,s collection with three varying lab...
(Date:11/21/2009)...Group ask whether there is a secret to ,alcohol re... London, UK (PRWEB) November 21, 2009...ree of the adult UK population drinking enough alc...d liver disease*, it is hardly a surprise that man...ammes and residential centres for help. However, f...
(Date:11/20/2009)...0 The United States Con...ke essential changes its health reform bill in ord...g and conscience protection on abortion, protect a...rong provisions for adequate affordability. ,, ..."enormous disappointment" that creates new and una...
(Date:11/20/2009)...swire-USNewswire/ -- The American Dental Associati...stration (FDA) to establish appropriate classifica... concern about the safety of whitening products th...rofessional consultation or examination by a denti...hemically based tooth whitening or bleaching agent...
Breaking Medicine News(10 mins):Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 2Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 3Health News:River Blindness (Onchocerciasis) Reduced By Nearly One-Third In At-Risk Populations In Six Countries 4Health News:Medelita Introduces Men's Lab Coat Collection 2Health News:Medelita Introduces Men's Lab Coat Collection 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 2Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 3Health News:Linwood Group Reveal How to Decide whether Alcohol Rehab Centres are a Success or Not 4Health News:U.S. Bishops Voice Disappointment in Abortion-Funding Provisions in Senate Health Bill, Urge Better Care for Immigrants and Affordability 2Health News:American Dental Association Petitions FDA to Classify, Regulate Tooth-Whitening Products 2
...ANNAH, Ga., Feb. 13 Founders Club will donate $5 ... Mammography Fund at St. Joseph,s/Candler. , , ...mmunity. Early detection is crucial in the fight a...lty golf retail stores across the United States. ,...
...al associate health coverage increases to more tha...-Mart Stores, Inc., (NYSE: WMT ) announced today...e coverage through its benefits plans for 2009 or ...endants in total - were covered by Wal-Mart,s plan...
...l Sense(TM) Device completes successful clinical e...nel Group announced the completion of the first st...onducted at Galenia Hospital in Cancun, Mexico by ...or 6 weeks to evaluate weight loss, satiety (lack ...
...t says the dark kind protects against cancer, alon...althDay News) -- Giving dark chocolate to your Val...rd your true love against cancer. , "The great new...Sally Scroggs, a health education manager at the U...
... HONG KONG, Feb. 13 /PRNewswire-Asia-FirstCall/ --...lthcare services provider, Golden Meditech,Company...8180) is pleased to,announce today the third quart...crease of 25% on a year-on-year basis. , Durin...
... BIRMINGHAM, Ala., Feb. 13 Emageon Inc. (Nasdaq:,...on technology systems for,hospitals and health car...he,$9 million that had been placed in escrow with ...owed funds became payable to Emageon,when the merg...
Other Medicine News:Health News:Founders Club Proudly Supports the St. Joseph's/Candler Mammography Fund 2Health News:Wal-Mart Health Care Benefits Enrollment Rises, Uninsured Rate Declines 2Health News:Wal-Mart Health Care Benefits Enrollment Rises, Uninsured Rate Declines 3Health News:Weight Loss Without Hunger! 2Health News:Chocolate for Your Valentine a Healthy Idea 2Health News:Golden Meditech Releases FY2008/09 Q3 Results 2Health News:Golden Meditech Releases FY2008/09 Q3 Results 3Health News:Emageon Receives Escrowed Funds and Terminates Merger Agreement 2Health News:Emageon Receives Escrowed Funds and Terminates Merger Agreement 3
DCR Set - Angled
IOL Manipulator - Sinskey
J Cortex Extrator - Angled Left
Cortex Extractor
Medicine Products: